Impact of HER2-Low Status in Metastatic Gastric Cancer: A Real-World Retrospective Cohort Study.

IF 2.5 3区医学 Q3 ONCOLOGY Oncology Pub Date : 2024-01-01 Epub Date: 2024-02-14 DOI:10.1159/000537839

Olcun Umit Unal, Seval Akay, Gurkan Gul, Murat Keser, Birsen Gizem Ozamrak, Dudu Solakoglu Kahraman, Mihriban Erdogan

{"title":"Impact of HER2-Low Status in Metastatic Gastric Cancer: A Real-World Retrospective Cohort Study.","authors":"Olcun Umit Unal, Seval Akay, Gurkan Gul, Murat Keser, Birsen Gizem Ozamrak, Dudu Solakoglu Kahraman, Mihriban Erdogan","doi":"10.1159/000537839","DOIUrl":null,"url":null,"abstract":"Introduction: Information regarding HER2-low tumors in metastatic gastric cancer is sparse. Our aim here was to determine the frequency of low HER2 expression in metastatic gastric cancer and to compare the clinicopathological characteristics, survival, and treatment response of HER2-low patients with HER2-zero patients.Methods: The clinicopathological features, treatment responses, and survival of HER2-low tumors and HER2-zero tumors were compared.Results: Of 226 patients, 71 (31.4%) had low HER2 expression and 155 (68.6%) had zero HER2 expression. HER2-low tumors were detected more frequently in older patients and in low-grade tumors than HER2-zero tumors (69% vs. 47.7%, p = 0.003, 16.9% vs. 3.8%, p < 0.001). On the contrary, HER2-zero tumors were more likely to be poor grade than HER2-low tumors (47% vs. 22.2%, p < 0.001). All patients received a first-line chemotherapy regimen. The disease control rate was not statistically different between both groups (40% vs. 46.4%, p = 0.11). The median survival was 12.05 (95% CI, 8.09-16.02) months in HER2-low patients and 10.41 (95% CI, 8.52-12.3) months in HER2-zero patients with no statistical difference (p = 0.73).Conclusion: HER2-low metastatic gastric cancer has a higher rate of being low grade than HER2-zero tumors. HER2-low metastatic gastric cancer is similar to HER2 zero in terms of chemotherapy response and survival.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000537839","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Information regarding HER2-low tumors in metastatic gastric cancer is sparse. Our aim here was to determine the frequency of low HER2 expression in metastatic gastric cancer and to compare the clinicopathological characteristics, survival, and treatment response of HER2-low patients with HER2-zero patients.

Methods: The clinicopathological features, treatment responses, and survival of HER2-low tumors and HER2-zero tumors were compared.

Results: Of 226 patients, 71 (31.4%) had low HER2 expression and 155 (68.6%) had zero HER2 expression. HER2-low tumors were detected more frequently in older patients and in low-grade tumors than HER2-zero tumors (69% vs. 47.7%, p = 0.003, 16.9% vs. 3.8%, p < 0.001). On the contrary, HER2-zero tumors were more likely to be poor grade than HER2-low tumors (47% vs. 22.2%, p < 0.001). All patients received a first-line chemotherapy regimen. The disease control rate was not statistically different between both groups (40% vs. 46.4%, p = 0.11). The median survival was 12.05 (95% CI, 8.09-16.02) months in HER2-low patients and 10.41 (95% CI, 8.52-12.3) months in HER2-zero patients with no statistical difference (p = 0.73).

Conclusion: HER2-low metastatic gastric cancer has a higher rate of being low grade than HER2-zero tumors. HER2-low metastatic gastric cancer is similar to HER2 zero in terms of chemotherapy response and survival.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HER2 低状态对转移性胃癌的影响：一项真实世界的回顾性队列研究。

简介有关转移性胃癌中HER2低表达肿瘤的信息很少。我们的目的是确定转移性胃癌中 HER2 低表达的频率，并比较 HER2 低表达患者与 HER2 零表达患者的临床病理特征、生存期和治疗反应：所有数据均通过医院计算机系统进行回顾性收集。我们根据 HER2 低肿瘤和 HER2 零肿瘤的临床病理特征、治疗反应和生存率对患者进行了分类：226例患者中，71例（31.4%）HER2低表达，155例（68.6%）HER2零表达。与HER2为零的肿瘤相比，HER2低表达肿瘤更多出现在年龄较大的患者和低级别肿瘤中（69% vs 47.7%，P = 0.003；16.9% vs 3.8%，P < 0.001）。所有患者都接受了一线化疗方案。两组患者的疾病控制率无统计学差异（40% vs 46.4%，P=0.11）。HER2低患者的中位生存期为12.05个月（95% CI，8.09-16.02个月），HER20零患者的中位生存期为10.41个月（95% CI，8.52-12.3个月），无统计学差异（P=0.73）：结论：与HER2为零的肿瘤相比，HER2为低的转移性胃癌的低分化率更高。在化疗反应和生存率方面，HER2-低转移性胃癌与HER2-零转移性胃癌相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.